Riferimento farmaci
Trastuzumab deruxtecan
Trastuzumab deruxtecan is a medicine in the class oncology. It is used for breast cancer.
- Classe del farmaco: Oncology
- Indicato per: breast cancer
Ultimo aggiornamento Fonti: US FDA label, EMA SmPC
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Oncology
- Codice ATC
- L01FD04
- Forme farmaceutiche comuni
- iniezione
- Dosaggi comuni
- 100 mg/5 ml
- Interazioni note
- 100 (Maggiore: 16 · Moderata: 78 · Minore: 6)
- Nomi commerciali
- 2
- Paesi e mercati
- 2
Per cosa si usa
Come agisce
HER2-directed antibody-drug conjugate: a humanized anti-HER2 IgG1 linked by a cleavable linker to DXd, a topoisomerase I inhibitor. After binding HER2, it is internalized and the linker is cleaved by lysosomal enzymes; released DXd causes DNA damage and apoptotic cell death.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
HER2-positive, HER2-low or HER2-ultralow metastatic breast cancer, HER2-mutant NSCLC, HER2-positive (IHC 3+) solid tumors: 5.4 mg/kg IV infusion every 3 weeks as monotherapy until disease progression or unacceptable toxicity
Gravidanza e allattamento
- Gravidanza
- Unsafe Can cause fetal harm; HER2-directed antibodies linked to oligohydramnios, pulmonary hypoplasia, skeletal abnormalities and neonatal death. No human data.
- Allattamento
- Unsafe No human milk data; advise not to breastfeed during treatment and for 7 months after last dose.
Effetti indesiderati segnalati
- Decreased white blood cell count
- Nausea
- Decreased hemoglobin
- Decreased neutrophil count
- Decreased lymphocyte count
- Fatigue
Avvertenze in evidenza
- Interstitial lung disease and pneumonitis, including severe, life-threatening and fatal cases, occur. Monitor for and investigate cough, dyspnea, fever and new respiratory symptoms. Permanently discontinue in all patients with Grade 2 or higher ILD/pneumonitis.
Chi deve prestare attenzione
- ILD/pneumonitis: monitor, evaluate with imaging, give corticosteroids; withhold or permanently discontinue per grade.
- Neutropenia including febrile neutropenia: monitor CBC before initiation and before each dose.
- Left ventricular dysfunction: assess LVEF before initiation and at regular intervals; not studied with LVEF less than 50%.
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (100)
- Ado-trastuzumab + Trastuzumab deruxtecan Major
- Azathioprine + Trastuzumab deruxtecan Major
- Bleomycin + Trastuzumab deruxtecan Major
- Dacarbazine + Trastuzumab deruxtecan Major
- Daunorubicin + Trastuzumab deruxtecan Major
- Deferiprone + Trastuzumab deruxtecan Major
- Doxorubicin + Trastuzumab deruxtecan Major
- Epirubicin + Trastuzumab deruxtecan Major
- Idarubicin + Trastuzumab deruxtecan Major
- Irinotecan + Trastuzumab deruxtecan Major
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Trastuzumab deruxtecan: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Trastuzumab deruxtecan used for?
Trastuzumab deruxtecan is a medicine in the class oncology. It is used for Breast cancer, Gastric cancer, Non-small cell lung cancer.
What side effects have been reported with Trastuzumab deruxtecan?
Decreased white blood cell count, Nausea, Decreased hemoglobin, Decreased neutrophil count, Decreased lymphocyte count, Fatigue. Serious warning: Interstitial lung disease and pneumonitis, including severe, life-threatening and fatal cases, occur.
Can Trastuzumab deruxtecan be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm; HER2-directed antibodies linked to oligohydramnios, pulmonary hypoplasia, skeletal abnormalities and neonatal death. No human data. Breastfeeding: Unsafe. No human milk data; advise not to breastfeed during treatment and for 7 months after last dose.
What does Trastuzumab deruxtecan interact with?
MediHelp lists 100 known interactions for Trastuzumab deruxtecan. Major: 16 · Moderate: 78 · Minor: 6. The most serious include Ado-trastuzumab, Azathioprine, Bleomycin.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
